David Young - 01 Apr 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
01 Apr 2025
Transactions value $
-$2,202
Form type
4
Filing time
11 Apr 2025, 17:16:01
Previous filing
18 Feb 2025
Next filing
18 Sep 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Options Exercise +17.3K +8.41% 223K 01 Apr 2025 Direct F1
transaction PCSA Common Stock Tax liability -$2.2K -5.35K -2.4% $0.41 217K 01 Apr 2025 Direct
holding PCSA Common Stock 31K 01 Apr 2025 By Young-Plaisance Revocable Trust
holding PCSA Common Stock 10.8K 01 Apr 2025 By Family Entities
holding PCSA Common Stock 18.5K 01 Apr 2025 By CorLyst, LLC
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distribution of vested restricted shares.